Prostate cancer
480 results
1 - 100
Prostate cancer 
Screening for prostate cancer- Lycopene for the prevention of prostate cancer
- 5‐alpha‐reductase inhibitors for prostate cancer prevention
- Bisphosphonates for advanced prostate cancer
- The association between vasectomy and prostate cancer
- PSA test in prostate cancer screening
- Hypofractionation for clinically localized prostate cancer
- Chemotherapy for hormone‐refractory prostate cancer
- Chemotherapy for hormone-refractory prostate cancer
- PSA for screening of prostate cancer
Quality of life varies after different prostate cancer treatments- Better estimate of prostate cancer risk based on the number of close relatives with prostate cancer and their age at diagnosis
- PREDICT Prostate online risk score accurately predicts the prognosis for men with nonmetastatic prostate cancer
- Radical prostatectomy versus deferred treatment for localised prostate cancer
- PSA screening for prostate cancer not recommended (USPSTF)
- Cryotherapy for localised prostate cancer
- Vitamin E supplementation increases risk of prostate cancer
- Five-alpha-reductase inhibitors for prostate cancer prevention
- Adjuvant radiotherapy following radical prostatectomy for prostate cancer
- Prostate cancer screening increases harm risk without decreasing mortality
- Hormones + radiation decrease mortality compared with radiation in prostate cancer
- Primary cryotherapy for localised or locally advanced prostate cancer
- Degarelix for treating advanced hormone‐sensitive prostate cancer
- Aspirin use and the risk of prostate cancer
- Maximal androgen blockade for advanced prostate cancer: Cochrane systematic review
- Increased vegetable consumption does not decrease prostate cancer progression
- Ask-tell-ask approach to discussing prostate cancer screening
- Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer
- Radical prostatectomy versus watchful waiting for newly diagnosed prostate cancer
- Psychosocial interventions for men with prostate cancer: Cochrane systematic review
- Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
- Approximately 12% of men regret prostate cancer treatment decisions (HCaP-NC)
- Dutasteride slows progression in men with low-grade prostate cancer (REDEEM)
- Observation = radical prostatectomy for most pts with localized prostate cancer (PIVOT)
- MA: Low-quality evidence finds DRE screening for prostate cancer inaccurate
- Men with localized prostate cancer have inaccurate perceptions of their prognosis
- Have the USPSTF recommendations against screening caused more aggressive prostate cancer?
- The full truth about prostate cancer screening is suppressed again (ERSPC)
- Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer
- Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer
- Sexual, urinary, and bowel dysfunction common after treatment for localized prostate cancer
- Adjuvant radiotherapy following radical prostatectomy for prostate cancer with high risk characteristics
- Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
- Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
- Prostatectomy for localized prostate cancer causes more functional problems without any survival benefit
- Neo‐adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
- Low-dose rate brachytherapy for men with localized prostate cancer: Cochrane systematic review
- Androgen deprivation therapy does not increase risk of CV death in men with prostate cancer
- Laparoscopic and robotic‐assisted versus open radical prostatectomy for the treatment of localised prostate cancer
- 5-a reductase inhibitor use prior to prostate cancer diagnosis is not associated with increased mortality
- Vitamins E and C and selenium do not reduce risk of prostate or total cancer in men
- Prediction of disease specific and overall survival in men with prostate cancer using the Decipher assay
- Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer
- Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
- USPSTF 2018 recommends counseling 55 to 69-year-old men on benefits and harms of prostate cancer screening (C recommendation)
- Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
- Posterior musculofascial reconstruction in robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer
- Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
- Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis